多奈哌齐的心血管治疗作用研究进展

Advances in the Effect of Donepezil in Cardiovascular Therapy

阿尔茨海默病(AD)为痴呆的主要类型,中枢神经系统胆碱能神经元的减少是其重要的发病机制之一。多奈哌齐作为一种高选择性、可逆性的胆碱酯酶抑制剂,能够通过对胆碱酯酶的抑制提高大脑皮质中的胆碱水平,从而改善患者的认知功能,是当前临床上治疗痴呆的一线药物之一,已有大量的临床研究证实其临床应用的有效性及安全性。许多痴呆患者同时合并心血管疾病,近期有研究表明多奈哌齐对心血管系统疾病亦有治疗作用。本文旨在对多奈哌齐目前的临床使用及心血管系统作用进行综述,并探讨其作用机制,比较其与加兰他敏和利斯的明的心血管作用效果,以指导多奈哌齐在临床中的进一步运用。

Alzheimer’s disease(AD)is the main type of dementia,and the reduction of cholinergic neurons in the central nervous system is one of its important pathogenesis.Donepezil,as a highly selective and reversible cholinesterase inhibitor,improves cognitive function of dementia patients by elevating acetylcholine level in cortex through inhibiting cholinesterase,and now is one of the front-line treatment drugs for dementia.A large number of clinical studies have confirmed the effectiveness and safety of the clinical application of donepezil.Many AD patients also suffer from cardiovascular diseases,and current researches have indicated a therapeutic effect of donepezil on cardiovascular diseases.This article aims to review the current clinical use of donepezil and its effects on cardiovascular system,and to explore its mechanism.This article compares the effects of donepezil with galantamine and rivastigmine on cardiovascular diseases in order to provide feedback to guide the further use of donepezil in the clinical practice.